Trial Profile
Phase I Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering AVXS-101
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Sep 2022
Price :
$35
*
At a glance
- Drugs Onasemnogene-abeparvovec (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; First in man; Registrational
- Acronyms START
- Sponsors Novartis Gene Therapies
- 13 Mar 2022 Results of post-hoc analysis from START, STR1VE-EU and STR1VE-US studies were presented at Novartis media release.
- 19 Nov 2020 Results of matching adjusted indirect comparison of Onasemnogene Abeparvovec and Nusinersen presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 19 May 2020 According to an AveXis media release, based on the STR1VE-US and START trials, the European Commission (EC) granted conditional approval for Zolgensma (onasemnogene abeparvovec) for the treatment of patients with 5q spinal muscular atrophy (SMA) and a clinical diagnosis of SMA Type 1; or for patients with 5q SMA. The approval covers babies and young children with SMA up to 21 kg according to the approved dosing guidance.